Institute of Pathology, Universitätsklinikum Jena, Germany.
J Mol Histol. 2010 Apr;41(2-3):89-99. doi: 10.1007/s10735-010-9274-6. Epub 2010 Jun 20.
Proteinase activated receptors (PAR 1-4) are membrane receptors with a unique way of activation by proteinases like thrombin, trypsin and matrix metalloproteinases which lead to a specific cellular response. To evaluate the significance of expression and co-expression of PAR in cancer we performed a survey on published data. A Pubmed literature search on "PAR, thrombin, cancer" was performed and 46 publications were selected for systematic review based on the availability of information on tumor type, material type, detection method and specification of positive cases. PAR-1 was found in 77.3% of malignant samples (n = 678), PAR-2 in 79.5% (n = 592), PAR-3 in 12.6% (n = 87) and PAR-4 in 54.9% (n = 153). PAR-1 and -2 were present in adenocarcinomas, melanomas, osteosarcomas, glioblastomas, meningiomas, leukaemias and squamous cell carcinomas. Presence of PAR-3 was limited to kidney and liver cancer. The data on PAR-4 expression was inconclusive. Those studies analysing PAR-1 and PAR-2 reported coexpression of the two receptors. PAR-1 and -2 are widely expressed in human tumors suggesting an important role in tumorigenesis and providing potential targets for therapy. PAR-3 and PAR-4 are less frequently detectable, their expression and potential role in tumorigenesis require further investigation.
蛋白酶激活受体(PAR1-4)是一类膜受体,其激活方式独特,可被凝血酶、胰蛋白酶和基质金属蛋白酶等蛋白酶激活,从而引发特定的细胞反应。为了评估蛋白酶激活受体在癌症中的表达和共表达的意义,我们对已发表的数据进行了调查。在 PubMed 上进行了关于“PAR、凝血酶、癌症”的文献检索,并根据肿瘤类型、材料类型、检测方法和阳性病例的具体情况,选择了 46 篇出版物进行系统综述。PAR-1 在 77.3%的恶性样本(n=678)中表达,PAR-2 在 79.5%(n=592)中表达,PAR-3 在 12.6%(n=87)中表达,PAR-4 在 54.9%(n=153)中表达。PAR-1 和 -2 在腺癌、黑色素瘤、骨肉瘤、胶质母细胞瘤、脑膜瘤、白血病和鳞状细胞癌中存在。PAR-3 的存在仅限于肝癌和肾癌。PAR-4 表达的数据尚无定论。那些分析 PAR-1 和 PAR-2 的研究报告了这两种受体的共表达。PAR-1 和 -2 在人类肿瘤中广泛表达,这表明它们在肿瘤发生中具有重要作用,并为治疗提供了潜在的靶点。PAR-3 和 PAR-4 的检测频率较低,其表达和在肿瘤发生中的潜在作用需要进一步研究。